BPC 157 Dosing (Common Protocols), Oral Subcutaneous, 500 mcg daily, Duration: 6 weeks, Intramuscular Peritendinous, 1 mg daily, Duration: 6 weeks, Note:, Not approved by FDA or Differences of first pass effect in the liver and intestine contribute to the stereoselective pharmacokinetics of rhynchophylline and isorhynchophylline epimers in rats ScienceDirect Is BPC 157 Banned? Oral vs. Injectable Forms Explained BPC 157 and the Difference Between an Evidence Gap and a Cover Up: What the entire human evidence base actually looks like, and the questions to ask next. WellFounded Founders Health & 1209_S7_article_14